The offering ($1,50 per Share) creates a great buying Opportunity .Now we know that Urocidin definitely works in Bladder Cancer means this is the next Blockbuster . Market-cap of 125 million$ is wayyy undervalued .Offering will be complete in mid December and the Rally will continue .This Stock is still under Radar .
This is a once in a Lifetime Opportunity .
Upcoming Milestones:
Start of the Global Phase 3 Study in 2010 << trigger a Milestone payment from Endo
Econiche approval in early 2011 (jan or feb) << Major share price driver
INVESTMENT HIGHLIGHTS
• With the recent positive results from Urocidin™’s bladder cancer Phase III
trial, Bioniche’s co-developer, Endo, has committed to invest considerable
financial and other corporate resources to an expanded bladder
cancer programme.
• Endo will commence a large, multi-country, multi-centre additional
clinical trial in refractory patients to gain registration of Urocidin™ in
the USA and Canada.
• Urocidin™ is expected to address a material unmet need in the treatment
of bladder cancer where the current standard of care, BCG, dates
back over 30 years and, the Company believes, has issues with respect
to its efficacy, safety and tolerability.
• Bioniche has invested more than 10 years and approximately C$130 million
in bringing the Urocidin™ technology to its current stage.
• The Animal Health division provides the Company with ongoing cash
flow and is a world market leader in a number of its product offerings.
• With full licensing approval in Canada, the Food Safety division has
developed the world’s first fully licensed cattle vaccine designed to
reduce the E. coli O157 infection rates in humans resulting from consumption
of contaminated beef products, as well as infections related
to exposure to contaminated water and produce.
• The Company is currently investing in the development of other food
safety vaccines including a vaccine to prevent Salmonella in swine,
cattle and chickens.
